Page 87 - Priority Review News Today

Dr. Armand Balboni appointed as Chair of the Board and moves to the U.S. Air Force Academy to take over as Principal Investigator for the ATI-1701 program; and Dr. Don Cilla promoted to President and... | November 14, 2022

Strong preclinical data, recently published in the International Journal of Molecular Sciences, from eight U.S government-funded in-vivo opaganib ...

/CNW/ - Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA), a subsidiary of Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that Health Canada has...

/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),...

/PRNewswire/ -- DelveInsights CAR T-cell Therapy Competitive Landscape – 2022 report provides comprehensive global coverage of available, marketed, and...

US FDA has set a Prescription Drug User Fee Act action date of 3 May 2023 This is the third major regulatory milestone for the vaccine candidate following acceptance of regulatory submissions in Europe and Japan Vaccine candidate has the potential to be the first available to help protect adults aged 60 years and older from lower respiratory tract

The FDA has accepted for Priority Review the NDA for TransCon PTH (palopegteriparatide) in adult patients with hypoparathyroidism.

/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),...

/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),...

The FDA’s Oncologic Drugs Advisory Committee voted against the approval of omburtamab for the treatment of neuroblastoma.